VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Therapeutic options in multiple sclerosis

Celia Oreja-Guevara • 24 May 2020
EAN 2020
Multiple Sclerosis and Related Disorders Antibodies Interferon-beta Ocrelizumab
Biology Treatment

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, outlines the current therapeutic options in multiple sclerosis and discusses the unmet needs in the field. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Celia Oreja-Guevara

2:39
Effects of menopause in women with MS: Cervantes scale
Celia Oreja-Guevara • 24 Mar 2023
2:46
Deciphering MS silent progression
Celia Oreja-Guevara • 24 Mar 2023
1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
2:16
CASTING: ocrelizumab safety profile in RRMS
Celia Oreja-Guevara • 20 Jun 2021

Related Videos

4:26
Decoding the genetic predisposition to PML in patients on natalizumab
Eli Hatchwell • 24 Oct 2023
1:50
A PML risk genetic test to identify at-risk patients on natalizumab
Eli Hatchwell • 24 Oct 2023
8:18
Advancements in PML genetic risk assessment
Eli Hatchwell • 24 Oct 2023
2:38
Influence of metabolites on inflammation and dietary implications
André Ortlieb Guerreiro Cacais • 23 Oct 2023
The content of VJNeurology is intended for healthcare professionals